Table 3.

Summary of tumor response data (RECIST): Best Response (N=22) and immunologic response (ELIspot) at day 50 and day 90 post-vaccination (N=20)

Primary	Stage	Best Response (RECIST)	Duration of Resp. (Months)	History of brain metastases	Site of progression	ELIspot*
						Day 50	Day 90
1. Unknown	M1a	PD	0	yes	brain, LN	n	NE
2. Cutaneous	M1b	SD	4	0	LN, lung	n	n
3. Cutaneous	M1c	PD	0	yes	subQ, LN	NE	NE
4. Cutaneous	M1a	SD	7	0	LN	p	p
5. Cutaneous	M1c	PR	2	0	liver	n	p
6. Cutaneous	M1b	PD	0	0	lung	p	NE
7. Cutaneous	M1b	SD	2	0	lung	n	n
8. Cutaneous	M1b	PD	0	0	lung	p	NE
9. Cutaneous	NE	NE	NE	yes	NE	NE	NE
10. Unknown	M1c	PD	0	0	LN, subQ	n	NE
11. Cutaneous	M1c	SD	4	yes	brain	p	n
12. Unknown	M1c	SD	2	yes	brain, lung	n	n
13. Unknown	M1c	SD	6	yes	brain	p	p
14. Cutaneous	M1a	PD	0	0	subQ	n	NE
15. Cutaneous	M1c	PD	0	yes	brain, bone, liver, lung	n	NE
16. Cutaneous	M1c	PD	0	yes	brain	p	NE
17. Cutaneous	M1c	PD	0	0	liver, lung, muscle, subQ	n	NE
18. Cutaneous	M1a	PD	0	0	liver, LN, subQ	n	NE
19. Cutaneous	M1a	PD	0	0	LN, subQ	n	NE
20. Cutaneous	M1c	SD	2	0	LN	p	p
21. Mucosal	M1b	SD	2	0	Lung	p	p
22. Cutaneous	M1b	PR	2+	0	NA	n	n

NE: non-evaluable; LN: lymph node; subQ: subcutaneous; NA: non-applicable; p=positive; n=negative

^*Twenty patients had day 50 samples for ELIspot testing and only 10 had day 90 samples